pharmacogenomics

Two people take the exact same dose of the same drug. One feels fine, one feels nothing, and a third gets seriously ill. Why? Often the answer is in their genes. Pharmacogenomics is the study of how your DNA shapes the way your body handles a drug — and using that knowledge to pick the right drug at the right dose for you.

Most of the action is in the genes for the enzymes that break drugs down, especially a liver family called cytochrome P450. People inherit different versions of these genes, so some are "fast metabolizers" who clear a drug so quickly it never works, while "slow metabolizers" build it up to toxic levels at a normal dose. Other genes affect the drug's target or the immune system. A few examples are now standard care: the blood thinner warfarin needs very different doses depending on two genes; the chemotherapy drug 6-mercaptopurine is dangerous at full dose for people with a faulty TPMT enzyme; and a single gene variant predicts a deadly skin reaction to the HIV drug abacavir, so patients are screened before they ever take it.

Pharmacogenomics is one of the most concrete, here-and-now pieces of precision medicine — a gene test before a prescription can prevent both useless treatment and dangerous side effects. But be honest about its scope. Genes are only part of the story: age, kidney and liver function, other drugs, and diet all matter too, so a clean gene test never guarantees a clean response. And the well-validated, actionable gene-drug pairs are still a small fraction of all medicines; for most drugs we cannot yet read your genome and predict the outcome.